The Effect of Warm Compress Therapy Using the TearRestore Eyelid Warming Mask on Meibomian Gland Function
Primary Purpose
Meibomian Gland Dysfunction
Status
Enrolling by invitation
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Tear Restore Mask
Sponsored by
About this trial
This is an interventional treatment trial for Meibomian Gland Dysfunction focused on measuring Dry eye
Eligibility Criteria
Inclusion Criteria:
- Adult participants (age 18-89) of any race, gender or ethnicity, diagnosed with meibomian gland dysfunction
- Symptom score greater than eight on the SPEED questionnaire
- Less than 75nm lipid layer thickness (LLT) utilizing the Lipiview II
- Less than 10 second tear break up time (average of 3 measurements)
Exclusion Criteria:
- Participants with less than 6/15 meibomian glands yielding liquid secretions in either eyelid
- Diagnosed with a systemic autoimmune condition including but not limited to Sjogren's or Lupus
Sites / Locations
- University of Colorado, Dept. of Ophthalmology
Arms of the Study
Arm 1
Arm 2
Arm Type
Other
Other
Arm Label
Single 10 minute session
Optional Extension
Arm Description
Study assessments will be performed before single 10 minute session of wearing the Tear Restore Mask and then study assessments will be repeated after the 10 minute single session has been completed.
Subjects can choose to extend use of the Tear Restore Mask at home for a period of 28 to 60 days. They will use the mask for a 10 minute time period one time per day and record the use in a diary.
Outcomes
Primary Outcome Measures
Standardized Patient Evaluation of Eye Dryness (SPEED) Questionnaire
The SPEED questionnaire will be completed by the subject prior to using the Tear Restore Mask and then repeated after the 10 minute session
Secondary Outcome Measures
Lipid Layer Thickness
The Lipid Layer Thickness will be measured prior to using the Tear Restore Mask using the Lipiview II machine and then repeated following the 10 minute session.
Tear Breakup Time
The Tear Breakup Time will be measured prior to using the Tear Restore Mask by the Clinician and then repeated following to 10 minute session.
Number of Meibomian Glands Yielding Liquid Secretions
The Number of Meibomian Glands Yielding Liquid Secretions will be counted by the clinician prior to using the Tear Restore Mask and then recounted by the clinician following to 10 minute session.
Full Information
NCT ID
NCT04309799
First Posted
March 12, 2020
Last Updated
February 16, 2022
Sponsor
University of Colorado, Denver
1. Study Identification
Unique Protocol Identification Number
NCT04309799
Brief Title
The Effect of Warm Compress Therapy Using the TearRestore Eyelid Warming Mask on Meibomian Gland Function
Official Title
The Effect of Warm Compress Therapy Using the TearRestore Eyelid Warming Mask on Symptoms and Signs of Meibomian Gland Function
Study Type
Interventional
2. Study Status
Record Verification Date
February 2022
Overall Recruitment Status
Enrolling by invitation
Study Start Date
November 20, 2020 (Actual)
Primary Completion Date
February 2023 (Anticipated)
Study Completion Date
February 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Colorado, Denver
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study plans to learn more about the effectiveness of the TearRestore eyelid warming mask on signs and symptoms of Meibomian Gland Dysfunction (MGD). MGD is a leading cause of dry eye symptoms. Warm compresses are a standard treatment recommended by physicians to treat those diagnosed with MGD. The study will investigate whether the TearRestore mask affects meibomian gland function and dry eye symptoms.
Detailed Description
The study will evaluate the effectiveness of the TearRestore eyelid warming mask on signs and symptoms of MGD. Warm compress treatments have been recommended as part of the standard of care by eye physicians, and are an important means in treating MGD. However, current treatment options suffer from varied temperature maintenance and poor compliance. The TearRestore™ mask offers patients a unique experience through providing sustained heat and the ability to see throughout the treatment, which will improve efficacy through improved compliance. If shown to be effective in altering Meibomian gland secretions at a single visit, this novel treatment could potentially offer the millions of patients suffering from MGD a more convenient and effective way to treat the condition.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Meibomian Gland Dysfunction
Keywords
Dry eye
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
50 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Single 10 minute session
Arm Type
Other
Arm Description
Study assessments will be performed before single 10 minute session of wearing the Tear Restore Mask and then study assessments will be repeated after the 10 minute single session has been completed.
Arm Title
Optional Extension
Arm Type
Other
Arm Description
Subjects can choose to extend use of the Tear Restore Mask at home for a period of 28 to 60 days. They will use the mask for a 10 minute time period one time per day and record the use in a diary.
Intervention Type
Device
Intervention Name(s)
Tear Restore Mask
Intervention Description
The Tear Restore Mask will be used for 10 minutes
Primary Outcome Measure Information:
Title
Standardized Patient Evaluation of Eye Dryness (SPEED) Questionnaire
Description
The SPEED questionnaire will be completed by the subject prior to using the Tear Restore Mask and then repeated after the 10 minute session
Time Frame
Up to 60 days
Secondary Outcome Measure Information:
Title
Lipid Layer Thickness
Description
The Lipid Layer Thickness will be measured prior to using the Tear Restore Mask using the Lipiview II machine and then repeated following the 10 minute session.
Time Frame
Up to 60 days
Title
Tear Breakup Time
Description
The Tear Breakup Time will be measured prior to using the Tear Restore Mask by the Clinician and then repeated following to 10 minute session.
Time Frame
Up to 60 days
Title
Number of Meibomian Glands Yielding Liquid Secretions
Description
The Number of Meibomian Glands Yielding Liquid Secretions will be counted by the clinician prior to using the Tear Restore Mask and then recounted by the clinician following to 10 minute session.
Time Frame
Up to 60 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
89 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adult participants (age 18-89) of any race, gender or ethnicity, diagnosed with meibomian gland dysfunction
Symptom score greater than eight on the SPEED questionnaire
Less than 75nm lipid layer thickness (LLT) utilizing the Lipiview II
Less than 10 second tear break up time (average of 3 measurements)
Exclusion Criteria:
Participants with less than 6/15 meibomian glands yielding liquid secretions in either eyelid
Diagnosed with a systemic autoimmune condition including but not limited to Sjogren's or Lupus
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Scott Hauswirth, MD
Organizational Affiliation
University of Colorado, Denver
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Colorado, Dept. of Ophthalmology
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
12. IPD Sharing Statement
Learn more about this trial
The Effect of Warm Compress Therapy Using the TearRestore Eyelid Warming Mask on Meibomian Gland Function
We'll reach out to this number within 24 hrs